S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
LON:GSK

GSK (GSK) Share Price, News & Analysis

GBX 1,706.80
+1.60 (+0.09%)
(As of 05:36 AM ET)
Today's Range
1,699.21
1,708.60
50-Day Range
1,521.20
1,711.20
52-Week Range
1,302.60
1,719.80
Volume
377,660 shs
Average Volume
7.28 million shs
Market Capitalization
£69.30 billion
P/E Ratio
1,422.33
Dividend Yield
3.75%
Price Target
GBX 1,658.75

GSK MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
2.7% Downside
GBX 1,658.75 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.56
Upright™ Environmental Score
News Sentiment
0.74mentions of GSK in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
£231.78 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.03 out of 5 stars

GSK stock logo

About GSK Stock (LON:GSK)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Stock Price History

GSK Stock News Headlines

GSK plc (LON:GSK) Insider Urs Rohner Buys 434 Shares of Stock
The AI Defense Stock Set to Soar
To protect our interests, The Pentagon has partnered with this small AI defense contractor - creating some of the most powerful AI defenses ever made.
GSK to cap out-of-pocket inhaler costs in US
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
GSK Mar 2024 41.000 call
GSK Mar 2024 34.000 put
How DEI is helping GSK get ahead of disease
GSK drug meets goal in late-stage gonorrhea study
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/29/2020
Ex-Dividend for 1/11 Dividend
11/16/2023
Dividend Payable
1/11/2024
Ex-Dividend for 4/11 Dividend
2/22/2024
Today
3/27/2024
Dividend Payable
4/11/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
70,212
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 1,658.75
High Stock Price Target
GBX 1,950
Low Stock Price Target
GBX 1,300
Potential Upside/Downside
-2.7%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
£4.93 billion
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£30.33 billion
Cash Flow
GBX 209.35 per share
Book Value
GBX 329 per share

Miscellaneous

Outstanding Shares
4,060,000,000
Free Float
N/A
Market Cap
£69.23 billion
Optionable
Not Optionable
Beta
0.26
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 55)
    CEO & Director
    Comp: $5.39M
  • Ms. Julie Belita Brown (Age 62)
    CFO & Executive Director
    Comp: $5.14M
  • Ms. Shobie Ramakrishnan (Age 53)
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer and Head of R&D
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 58)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs

Should I Buy GSK Stock? GSK Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Monday, March 25, 2024 at 11:49 AM.

Pros

Here are some ways that investors could benefit from investing in GSK plc:

  • GSK plc has shown consistent growth in revenue and earnings, indicating financial stability and potential for returns.
  • Recent analyst ratings and target prices suggest a positive outlook for the stock, with potential upside for investors.
  • The company's stock price has been performing well, showing resilience and potential for capital appreciation.
  • GSK plc has a diverse portfolio of pharmaceutical products, reducing risk associated with dependency on a single product.
  • Strong institutional investor interest in GSK plc indicates confidence in the company's future performance.

Cons

Investors should be bearish about investing in GSK plc for these reasons:

  • GSK plc's debt-to-equity ratio is relatively high, which may pose risks in terms of financial leverage and interest payments.
  • The company's P/E ratio is high, suggesting the stock may be overvalued compared to its earnings potential.
  • GSK plc's beta indicates lower volatility compared to the market, potentially limiting short-term trading opportunities for investors.
  • The current ratio of GSK plc is below 1, indicating potential liquidity challenges in meeting short-term obligations.
  • Market competition and regulatory challenges in the pharmaceutical industry could impact GSK plc's growth prospects and market share.

GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price target for 2024?

7 Wall Street analysts have issued 1 year price targets for GSK's stock. Their GSK share price targets range from GBX 1,300 to GBX 1,950. On average, they expect the company's stock price to reach GBX 1,658.75 in the next year. This suggests that the stock has a possible downside of 2.7%.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2024?

GSK's stock was trading at GBX 1,450.20 at the start of the year. Since then, GSK shares have increased by 17.6% and is now trading at GBX 1,704.80.
View the best growth stocks for 2024 here
.

How were GSK's earnings last quarter?

GSK plc (LON:GSK) announced its quarterly earnings results on Wednesday, July, 29th. The company reported $56.90 EPS for the quarter. GSK had a net margin of 16.25% and a trailing twelve-month return on equity of 46.38%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a dividend on Wednesday, January 31st. Stockholders of record on Thursday, February 22nd will be given a dividend of GBX 16 per share on Thursday, April 11th. This represents a yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is a boost from the stock's previous dividend of GBX 14. The official announcement can be seen at this link.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (LON:GSK) pays an annual dividend of GBX 64 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 5,333.33%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AstraZeneca (AZN), General Electric (GE), Royal Dutch Shell (RDSB), Vodafone Group Public (VOD), Intel (INTC), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), Barclays (BARC) and Gilead Sciences (GILD).

How do I buy shares of GSK?

Shares of GSK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:GSK) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners